$CNSP
CNS Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823008144 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.108M $1.123M $2.153M
YoY Change -48.54% -7.25% 140.15%
% of Gross Profit
Research & Development $4.272M $3.411M $3.349M
YoY Change 27.54% 54.47% 76.6%
% of Gross Profit
Depreciation & Amortization $950.00 $3.180K $2.380K
YoY Change -60.08% 13.57% -31.81%
% of Gross Profit
Operating Expenses $5.379M $4.534M $5.502M
YoY Change -2.23% 32.61% 97.0%
Operating Profit -$4.534M
YoY Change 32.61%
Interest Expense $4.120K $1.838K -$2.310K
YoY Change -278.35% 241.64% 3.13%
% of Operating Profit
Other Income/Expense, Net $11.05K
YoY Change -2152.97%
Pretax Income -$5.375M -$4.523M -$5.504M
YoY Change -2.34% 32.26% 96.92%
Income Tax
% Of Pretax Income
Net Earnings -$5.375M -$4.523M -$5.504M
YoY Change -2.34% 32.26% 96.92%
Net Earnings / Revenue
Basic Earnings Per Share -$1.08
Diluted Earnings Per Share -$1.06 -$1.08 -$3.71
COMMON SHARES
Basic Shares Outstanding 5.249M shares 4.202M shares 40.03M shares
Diluted Shares Outstanding 4.177M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $548.7K $909.6K $10.06M
YoY Change -94.54% -87.06% 100.93%
Cash & Equivalents $548.7K $909.5K $10.06M
Short-Term Investments
Other Short-Term Assets $1.042M $1.152M $2.509M
YoY Change -58.46% -31.12% 1.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.591M $2.062M $12.56M
YoY Change -87.34% -76.3% 68.03%
LONG-TERM ASSETS
Property, Plant & Equipment $4.930K $3.470K $5.664K
YoY Change -12.96% -59.28% -64.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $104.8K $262.7K $482.8K
YoY Change -78.3% -71.72% -61.8%
Total Long-Term Assets $109.7K $266.2K $488.5K
YoY Change -77.55% -71.61% -61.84%
TOTAL ASSETS
Total Short-Term Assets $1.591M $2.062M $12.56M
Total Long-Term Assets $109.7K $266.2K $488.5K
Total Assets $1.701M $2.328M $13.05M
YoY Change -86.97% -75.84% 49.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.832M $4.027M $3.682M
YoY Change 58.4% 300.67% 141.78%
Accrued Expenses $828.4K
YoY Change 268.26%
Deferred Revenue
YoY Change
Short-Term Debt $300.8K $41.90K $449.9K
YoY Change -33.13% 6.72% 5.61%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.133M $4.069M $4.920M
YoY Change 24.65% 226.99% 130.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.133M $4.069M $4.920M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.133M $4.069M $4.920M
YoY Change 24.65% 226.99% 130.4%
SHAREHOLDERS EQUITY
Retained Earnings -$69.57M -$64.19M -$50.72M
YoY Change 37.17% 43.44% 44.97%
Common Stock $6.214K $4.207K $1.617K
YoY Change 284.29% -89.49% -94.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.432M -$1.741M $8.133M
YoY Change
Total Liabilities & Shareholders Equity $1.701M $2.328M $13.05M
YoY Change -86.97% -75.84% 49.05%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$5.375M -$4.523M -$5.504M
YoY Change -2.34% 32.26% 96.92%
Depreciation, Depletion And Amortization $950.00 $3.180K $2.380K
YoY Change -60.08% 13.57% -31.81%
Cash From Operating Activities -$2.536M -$3.374M -$2.305M
YoY Change 10.02% 86.11% -28.78%
INVESTING ACTIVITIES
Capital Expenditures $2.160K $1.740K $0.00
YoY Change -215.23% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.160K -$1.740K $0.00
YoY Change 15.23% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.178M 9.560K 5.333M
YoY Change -59.17% -108.16% -6538.8%
NET CHANGE
Cash From Operating Activities -2.536M -3.374M -2.305M
Cash From Investing Activities -2.160K -1.740K 0.000
Cash From Financing Activities 2.178M 9.560K 5.333M
Net Change In Cash -360.8K -3.366M 3.028M
YoY Change -111.92% 74.27% -191.16%
FREE CASH FLOW
Cash From Operating Activities -$2.536M -$3.374M -$2.305M
Capital Expenditures $2.160K $1.740K $0.00
Free Cash Flow -$2.539M -$3.375M -$2.305M
YoY Change 10.11% 86.36% -28.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001729427
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39126
dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
946-9185
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CNSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5248598 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
909547 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10055407 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1152298 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2509238 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
2061845 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12564645 usd
CY2023Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
262731 usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
482806 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3470 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5664 usd
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
266201 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
488470 usd
CY2023Q3 us-gaap Assets
Assets
2328046 usd
CY2022Q4 us-gaap Assets
Assets
13053115 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4026894 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4510291 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
41904 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4068798 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4920259 usd
CY2023Q3 us-gaap Liabilities
Liabilities
4068798 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4920259 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4207068 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4207068 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1617325 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1617325 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4207 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1617 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62446694 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58846916 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64191653 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50715677 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1740752 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2328046 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13053115 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1123268 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1211102 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3661853 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3814513 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3410572 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2207913 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9823884 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6318055 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4533840 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3419015 usd
us-gaap Operating Expenses
OperatingExpenses
13485737 usd
us-gaap Operating Expenses
OperatingExpenses
10132568 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4533840 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3419015 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13485737 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10132568 usd
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
12883 usd
CY2022Q3 us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
us-gaap Interest Income Operating
InterestIncomeOperating
20685 usd
us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
1838 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
538 usd
us-gaap Interest Expense
InterestExpense
10924 usd
us-gaap Interest Expense
InterestExpense
4715 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11045 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-538 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9761 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4715 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4522795 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3419553 usd
us-gaap Net Income Loss
NetIncomeLoss
-13475976 usd
us-gaap Net Income Loss
NetIncomeLoss
-10137283 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.67
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.67
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4177069 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1334417 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3327636 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1321065 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4177069 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1334417 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3327636 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1321065 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
609 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290313 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3491831 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1969107 usd
CY2023Q2 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
725059 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289670 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4021234 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2454433 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
132851 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
194759 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4522795 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1740752 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6163197 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10625786 usd
CY2022Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
2616 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
336685 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3151778 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13976506 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
286841 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3565952 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10697395 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289721 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3419553 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7567563 usd
us-gaap Net Income Loss
NetIncomeLoss
-13475976 usd
us-gaap Net Income Loss
NetIncomeLoss
-10137283 usd
us-gaap Share Based Compensation
ShareBasedCompensation
774742 usd
us-gaap Share Based Compensation
ShareBasedCompensation
913247 usd
us-gaap Depreciation
Depreciation
3181 usd
us-gaap Depreciation
Depreciation
9375 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-757 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2635 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1577015 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1134824 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-483397 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-175290 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11603678 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8252492 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1744 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4423 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1744 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4423 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
368064 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
348534 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
725668 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2616 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2101958 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10625786 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2459562 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10279868 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9145860 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2022953 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5004517 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
909547 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7027470 usd
us-gaap Interest Paid Net
InterestPaidNet
10924 usd
us-gaap Interest Paid Net
InterestPaidNet
5782 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80A_eus-gaap--NatureOfOperations_zSXLOUXjz314" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_820_zAF1DcaJV508">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
659547 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwpYjtlLbBCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassification</b></span><b> - </b><span style="font-family: Times New Roman, Times, Serif">Certain reclassifications may have been made to our prior year’s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
449874 usd
CY2022Q4 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0588 pure
CY2022Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-10-31
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
41904 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29988 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M14D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4318 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
725668 usd

Files In Submission

Name View Source Status
0001683168-23-008144-index-headers.html Edgar Link pending
0001683168-23-008144-index.html Edgar Link pending
0001683168-23-008144.txt Edgar Link pending
0001683168-23-008144-xbrl.zip Edgar Link pending
cnsp-20230930.xsd Edgar Link pending
cns_ex3101.htm Edgar Link pending
cns_ex3102.htm Edgar Link pending
cns_ex3201.htm Edgar Link pending
cns_ex3202.htm Edgar Link pending
cns_i10q-093023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
cnsp-20230930_lab.xml Edgar Link unprocessable
cnsp-20230930_pre.xml Edgar Link unprocessable
cnsp-20230930_def.xml Edgar Link unprocessable
cnsp-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cns_i10q-093023_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending